Xalkori gets approval for ROS1-positive NSCLC in Japan and Taiwan

OxOnc Development L.P. (Princeton, N.J.) said partner Pfizer Inc. (NYSE:PFE) received approval in Japan and Taiwan for Xalkori crizotinib (PF-02341066) to treat c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive advanced non-small cell lung cancer (NSCLC).

Under a 2013 deal, Pfizer partnered with OxOnc to conduct an Asian pivotal trial to evaluate Xalkori in patients with advanced NSCLC with ROS1 gene rearrangements. OxOnc said it is eligible to milestone payments from Pfizer upon regulatory approval in some countries, but did not disclose terms (see BioCentury, Feb. 18, 2013)...